Investment in Swiss startups declined by 8.5% in 2024, with total funding dropping to CHF 2.4 billion and financing rounds falling to 357. The Swiss Venture Capital Report reveals a shift in investor focus, as large funding rounds were scarce, leading to more evenly distributed investments. While ICT and fintech sectors saw significant declines, the biotech sector rebounded, attracting CHF 739.2 million, a 50% increase from the previous year. Despite the downturn, two-thirds of surveyed investors are optimistic about increased investments in 2025, indicating potential recovery in startup financing and IPO activity, starting with BioVersys’s upcoming IPO.